Respiratory inhaler devices are essential tools for delivering medication directly into the lungs for the treatment and management of respiratory conditions such as asthma, chronic obstructive ...

According to the report, the 'respiratory inhaler devices market' was valued at $32.4 billion in 2024, and is estimated to reach $51.9 billion by 2034, growing at a CAGR of 4.8% from 2025 to 2034.The ...

The characteristics of an ideal inhaler are based around the design and formulation of the device, patient use and the clinical effect, together with concordance and patient preference. To ensure ...

NEWARK, Del., December 02, 2025--(BUSINESS WIRE)--CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget ...

Molex LLC, parent to medical supplier Phillips-Medisize LLC, has signed an agreement through its Molex Asia Holdings Ltd. affiliate to acquire Vectura Group Ltd. from Vectura Fertin Pharma Inc., a ...